UPMC Enterprises has co-led a seed round for the gene therapy developer.
Code Biotherapeutics, a US-based gene therapy developer, has collected $10m in seed financing from investors co-led by UPMC Enterprises, the investment arm of University of Pittsburgh-affiliated health system UPMC.
4Bio Capital co-led the round, while Takeda Ventures, the corporate venture capital arm of pharmaceutical firm Takeda, as well as CureDuchenne Ventures, JDRF T1D Fund and New Enterprise Associates also took part.
Code Bio is working on treatments for a broad range of genetic disorders, with an initial focus…
